Nav: Home

Flu vaccine is safe for hospitalized patients

January 08, 2019

Hospitalized patients who received the flu vaccine had no increased risk of outpatient visits or hospital readmission within seven days of discharge, according to a Kaiser Permanente study published today in Mayo Clinic Proceedings.

The study also showed that vaccinating hospital patients did not increase the risk of fever or rates of laboratory evaluations for infection. It also showed that the vast majority of patients who were not vaccinated during their hospital stay remained unvaccinated for the full flu season.

"We know rates of inpatient flu vaccination are low, often due to physician concerns that the vaccine could complicate healing or delay hospital discharge," said Sara Y. Tartof, PhD, MPH, study lead author, Kaiser Permanente Southern California Department of Research & Evaluation. "Our findings demonstrate that not vaccinating patients during a hospitalization may be a missed opportunity. Right now, only 28 percent of patients not already vaccinated prior to hospitalization are being vaccinated before they leave the hospital."

This study builds upon previous research that showed surgical patients who received the flu vaccine during their hospital stay did not have increased risks of complications or delay in discharge compared to surgical patients who were not vaccinated during their stay.

The flu is a highly contagious respiratory infection that can cause serious complications, hospitalizations and, in some cases, even death. Some people -- such as older adults, young children and people with certain health conditions -- are at high risk for serious complications if they get the flu. In addition to recommending annual flu vaccination for people ages 6 months and older, the Centers for Disease Control and Prevention recommends hospitalized patients who are eligible receive the flu vaccine before discharge.

This retrospective cohort study looked at the electronic health records of more than 250,000 patients ages 6 months and older who were hospitalized in a Kaiser Permanente hospital in Southern California during any of three flu seasons from 2011 to 2014 with admission and discharge dates between September 1 and March 31 of the following calendar year.

Researchers found:
  • 71 percent of patients vaccinated during their hospital stay were vaccinated on the day of discharge.
  • 74 percent of those who miss the opportunity to vaccinate before or during hospitalization remained unvaccinated throughout the season.
  • No increased risk of hospital readmissions, outpatient visits, fever, or clinical evaluations for infection among patients who received the flu vaccine during their hospital stay.
"This research backs up what many physicians have known intuitively for some time: Giving patients the flu vaccine while they are hospitalized is convenient and, most important, safe," said Bruno J. Lewin, MD, a family practice physician at the Kaiser Permanente Los Angeles Medical Center. "Unless there are contraindications, physicians should have no hesitation to vaccinate patients with the flu vaccine while they are hospitalized."
-end-
The study was funded through the Vaccine Safety Datalink by the Centers for Disease Control and Prevention.

Other authors of the study include senior author Steven J. Jacobsen, MD, PhD; and Lei Qian, PhD; In-Lu Amy Liu, MS; Hung Fu Tseng, PhD; Lina S. Sy, MPH; and Rulin C. Hechter, MD, PhD, of the Kaiser Permanente Southern California Department of Research & Evaluation; and Bruno J. Lewin, MD, with the Southern California Permanente Medical Group.

Vaccine research is an active area of study at Kaiser Permanente.

About the Kaiser Permanente Southern California Department of Research & Evaluation

The Department of Research & Evaluation conducts high-quality, innovative research into disease etiology, prevention, treatment and care delivery. Investigators conduct epidemiologic research, health services research, biostatistics research, and behavioral research as well as clinical trials. Major areas of study include chronic disease, infectious disease, cancer, drug safety and effectiveness, and maternal and child health. Headquartered in Pasadena, California, the department focuses on translating research to practice quickly to benefit the health and lives of Kaiser Permanente Southern California members and the general public. Visit kp.org/research.

About Kaiser Permanente

Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America's leading health care providers and not-for-profit health plans. Founded in 1945, Kaiser Permanente has a mission to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve more than 12.2 million members in eight states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal Permanente Medical Group physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health. For more information, go to kp.org/share.

Kaiser Permanente

Related Flu Vaccine Articles:

Recommendation against inhaled flu vaccine is good -- for now
Recent federal recommendations against offering the inhaled nasal influenza vaccine due to lack of effectiveness could lead to more flu illness in the US if the inhaled vaccine becomes effective again or if not having the choice of the needle-less vaccine substantially reduces immunization rates, according to a new analysis led by University of Pittsburgh School of Medicine scientists.
'Dose sparing' flu vaccine could boost productivity and vaccine availability
The currently licensed seasonal trivalent influenza vaccines contain 15 micrograms of viral hemagglutinin protein per strain for adults, and up to 60 micrograms for elderly individuals; however, due to recent shortages, reducing these doses would be highly desirable.
Parental concerns reduce uptake of child flu vaccine
The first study investigating parental attitudes towards the UK's child flu vaccine has found concerns about safety and side effects may negatively influence uptake, and recommends that public health messages need to be reinforced.
In a bad flu season, high-dose flu vaccine appeared better at preventing deaths in seniors
Older adults are at high risk for serious complications from flu and account for a majority of flu-related deaths and hospitalizations.
Team uncovers cellular responses to bird flu vaccine
New research from Vanderbilt eavesdrops on gene expression in human immune system cells before and after vaccination against bird flu, exposing cellular responses associated with a vaccine constituent called AS03, short for adjuvant system 03.
Flu vaccine's effectiveness can be improved, new findings suggest
A team of engineers and scientists at the University of Texas at Austin is reporting new findings on how the influenza vaccine produces antibodies that protect against disease, research that suggests that the conventional flu vaccine can be improved.
Antibodies triggered by avian influenza virus vaccine illuminate a new path toward a universal flu vaccine
Diverse antibodies induced in humans by vaccination with an avian influenza virus vaccine may offer broader, more durable protection against multiple strains of influenza than today's vaccines typically provide.
Novel strategy may improve seasonal flu vaccine effectiveness
New findings describe a novel strategy for predicting how circulating influenza viruses will evolve, an approach that may help scientists create better seasonal influenza vaccines.
New strategy could yield more precise seasonal flu vaccine
A team of researchers led by University of Wisconsin-Madison School of Veterinary Medicine virologist Yoshihiro Kawaoka describes a novel strategy to predict the antigenic evolution of circulating influenza viruses and give science the ability to more precisely anticipate seasonal flu strains.
Infant-friendly flu vaccine developed with key protein
According to the World Health Organization, influenza causes serious illness among millions of people each year, resulting in 250,000 to 500,000 deaths.

Related Flu Vaccine Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Setbacks
Failure can feel lonely and final. But can we learn from failure, even reframe it, to feel more like a temporary setback? This hour, TED speakers on changing a crushing defeat into a stepping stone. Guests include entrepreneur Leticia Gasca, psychology professor Alison Ledgerwood, astronomer Phil Plait, former professional athlete Charly Haversat, and UPS training manager Jon Bowers.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".